[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2003055518A1 - Procede de traitement d'etats immuno-pathologiques et medicament correspondant - Google Patents

Procede de traitement d'etats immuno-pathologiques et medicament correspondant Download PDF

Info

Publication number
WO2003055518A1
WO2003055518A1 PCT/RU2002/000384 RU0200384W WO03055518A1 WO 2003055518 A1 WO2003055518 A1 WO 2003055518A1 RU 0200384 W RU0200384 W RU 0200384W WO 03055518 A1 WO03055518 A1 WO 03055518A1
Authority
WO
WIPO (PCT)
Prior art keywords
limφοtsiτοv
treatment
anτiτel
immunopathosis
curing
Prior art date
Application number
PCT/RU2002/000384
Other languages
English (en)
Russian (ru)
Inventor
Oleg Iliich Epshtein
Original Assignee
Goldberg, Evgeny Danilovich
Dygay, Alexandr Mikhailovich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Goldberg, Evgeny Danilovich, Dygay, Alexandr Mikhailovich filed Critical Goldberg, Evgeny Danilovich
Priority to AU2002313946A priority Critical patent/AU2002313946A1/en
Publication of WO2003055518A1 publication Critical patent/WO2003055518A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Definitions

  • the invention is available in the field of medicine and may be used for the treatment of medications that do not have a pronounced treatment of immune disease, and
  • the predominant use of the mixture is various, preferably commercially available, medicinal dilutions of the medicinal product.
  • the medicinal product is prepared by the following method. On the basis of the data on the basic antipyretic structure of the SB4 molecule, the recombinant technology is used to generate the generative molecule C04 or
  • SIGNIFICANT FOX (DR. 26) 3 method of a positive antipyretic synthesis produces a polypeptide fragment of the molecule.
  • the resulting recombinant molecule or its component is used as an immunogen for immunization of laboratory live animals for the purpose of receiving immune antibodies or for the purpose of immunotherapy. Obtained antibodies are cleared by the method of an affirmative process.
  • the current processing in the process of reducing the concentration is also possible to carry out ultrasound, electric or other physical interference.
  • SIGNIFICANT FOX (DR. 26) ⁇ azvedeniya ⁇ 4, or in the form s ⁇ i ⁇ vy ⁇ v ⁇ dny ⁇ ⁇ as ⁇ v ⁇ v or ⁇ able ⁇ (g ⁇ anul) ⁇ luchenny ⁇ ⁇ u ⁇ em ⁇ i ⁇ yvaniya saturation d ⁇ s ⁇ de ⁇ zhascheg ⁇ sya in le ⁇ a ⁇ s ⁇ venn ⁇ y ⁇ me na ⁇ lni ⁇ elya ⁇ entsi ⁇ vannym ⁇ as ⁇ v ⁇ m or ne ⁇ s ⁇ eds ⁇ vennym introduction ⁇ sledneg ⁇ in zhid ⁇ uyu le ⁇ a ⁇ s ⁇ vennuyu ⁇ mu.
  • connection ⁇ li ⁇ ezis ⁇ en ⁇ n ⁇ s ⁇ yu ⁇ ⁇ iv ⁇ ube ⁇ uleznym ⁇ e ⁇ a ⁇ a ⁇ am 1 ⁇ yada were assigned sve ⁇ malye d ⁇ zy a ⁇ ivi ⁇ vanny ⁇ m ⁇ n ⁇ l ⁇ nalny ⁇ an ⁇ i ⁇ el ⁇ ⁇ e ⁇ idn ⁇ mu ⁇ agmen ⁇ u m ⁇ le ⁇ uly SE4 chel ⁇ ve ⁇ a (mixture g ⁇ me ⁇ a ⁇ iches ⁇ i ⁇ ⁇ azvedeny C12 + C30 + C200) - ⁇ ⁇ able ⁇ e 1 to 5 ⁇ assasyvaniya v ⁇ ⁇ u ⁇ az in su ⁇ i.
  • ⁇ 4 people (a mixture of homogenous dilutions ⁇ 12 + ⁇ 30 + ⁇ 10) - there is only 1 tablet for absorbing 5 times a day.
  • the patient's body normalized, the temperature of the body improved, the general condition improved, and the rate of failure decreased.
  • a quantity of C ⁇ 4 + 420 cells per 1 ⁇ l, mycobacteriosis and herpes infection decreased, the incidence of the disease was 36.8, 3%. Recommend treatment.
  • step 1 body 38 ° C, expressed loss
  • SIGNIFICANT FOX (DR. 26) 6 leukemia, antinuclearial factor 1: 128.
  • SIGNIFICANT FOX (DR. 26) In studying the effect of activated antibodies on small doses of antibodies to the C4 molecule on the induction of immunological therapy in the Ukrzys-Ag family (180-200g), there were P ⁇ sle indu ⁇ tsii a ⁇ i ⁇ a ⁇ ysy ⁇ luchali ⁇ eg ⁇ z a ⁇ ivi ⁇ vannye ( ⁇ entsi ⁇ vannye) sve ⁇ malye d ⁇ zy ⁇ li ⁇ l ⁇ nalny ⁇ ⁇ lichi ⁇ an ⁇ i ⁇ el ⁇ ⁇ e ⁇ mbinan ⁇ n ⁇ y m ⁇ le ⁇ ule S ⁇ 4 chel ⁇ ve ⁇ a (mixture g ⁇ me ⁇ a ⁇ iches ⁇ i ⁇ ⁇ azvedeny B6 + C200) - ⁇ 1.5 ml v ⁇ dn ⁇ g ⁇ ⁇ as ⁇ v ⁇ a in su ⁇ i vmes ⁇ e with ⁇ e ⁇ alnym administration of 0.5 mg ⁇ llagena 2

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Selon l'invention, le procédé de traitement d'états immuno-pathologiques consiste à administrer des doses extrêmement faibles d'anticorps immuns ou naturels, monoclonaux ou polyclonaux, activés (potentialisés) des marquers de lymphocytes T auxiliaires (à la molécule CD4 des lymphocytes T), la forme activée étant obtenue par la dilution multiple répétée et par le traitement extérieur. Le médicament destiné au traitement d'états immuno-pathologiques comprend des doses extrêmement faibles d'anticorps monoclonaux, polyclonaux ou naturels activés des marquers de lymphocytes T auxiliaires (à la molécule CD4 des lymphocytes T), la forme activée étant obtenue par la dilution multiple répétée et par le traitement extérieur fondé principalement sur une technique homéopathique.
PCT/RU2002/000384 2001-12-26 2002-08-13 Procede de traitement d'etats immuno-pathologiques et medicament correspondant WO2003055518A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002313946A AU2002313946A1 (en) 2001-12-26 2002-08-13 Method for curing immunopathosis and medicinal agent for carrying out said method

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2001134982 2001-12-26
RU2001134982/15A RU2001134982A (ru) 2001-12-26 2001-12-26 Способ коррекции иммунного ответа и лекарственное средство

Publications (1)

Publication Number Publication Date
WO2003055518A1 true WO2003055518A1 (fr) 2003-07-10

Family

ID=20254870

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/RU2002/000384 WO2003055518A1 (fr) 2001-12-26 2002-08-13 Procede de traitement d'etats immuno-pathologiques et medicament correspondant

Country Status (3)

Country Link
AU (1) AU2002313946A1 (fr)
RU (1) RU2001134982A (fr)
WO (1) WO2003055518A1 (fr)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7700096B2 (en) 2002-08-02 2010-04-20 Oleg Iliich Epshtein Medicinal agent for treating erectile dysfunction
US8066992B2 (en) 2002-08-02 2011-11-29 Oleg Iliich Epshtein Medicament and a method of treating a pathological syndrome
WO2012017328A3 (fr) * 2010-08-06 2012-04-05 Oleg Iliich Epshtein Composition pharmaceutique à combinaison et méthodes de traitement et de prévention des maladies infectieuses
WO2012017327A3 (fr) * 2010-08-06 2012-04-12 Oleg Iliich Epshtein Composition pharmaceutique et méthodes de traitement et de prévention des maladies provoquées par le vih ou associées au vih
WO2012017323A3 (fr) * 2010-08-06 2012-04-12 Oleg Iliich Epshtein Composition pharmaceutique et méthodes de traitement et de prévention des maladies provoquées par le vih ou associées au vih
WO2012017322A3 (fr) * 2010-08-06 2012-04-19 Oleg Iliich Epshtein Composition pharmaceutique et procédé d'inhibition de la production ou d'amplification de l'élimination de la protéine p24
EP2601967A1 (fr) * 2010-08-06 2013-06-12 Oleg Iliich Epshtein Médicament destiné à la prévention et au traitement des maladies provoquées par le vih ou associées au vih, y compris du sida
CN103282384A (zh) * 2010-07-15 2013-09-04 奥列格·伊里奇·爱泼斯坦 复合药物组合物以及对泌尿生殖系统障碍进行治疗的方法
US8535664B2 (en) 2000-06-20 2013-09-17 Oleg I. Epshtein Method of treating a pathological syndrome and a pharmaceutical agent
US8637030B2 (en) 2010-07-15 2014-01-28 Oleg I. Epshtein Combination pharmaceutical composition and methods of treating functional diseases or conditions of gastrointestinal tract

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5733572A (en) * 1989-12-22 1998-03-31 Imarx Pharmaceutical Corp. Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles
RU98109384A (ru) * 1998-05-22 2000-03-10 О.В. Чернова Способ коррекции нарушенного иммунного гомеостаза и лекарственное средство
RU2156621C1 (ru) * 1999-03-04 2000-09-27 Эпштейн Олег Ильич Нейротропное лекарственное средство
RU2161034C1 (ru) * 2000-08-02 2000-12-27 Новицкий Юрий Алексеевич Иммунокорригирующее протеоселеновое средство и способ иммунокоррекции

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2187334C2 (ru) * 1998-05-22 2002-08-20 Эпштейн Олег Ильич Способ коррекции нарушенного иммунного гомеостаза и лекарственное средство

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5733572A (en) * 1989-12-22 1998-03-31 Imarx Pharmaceutical Corp. Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles
RU98109384A (ru) * 1998-05-22 2000-03-10 О.В. Чернова Способ коррекции нарушенного иммунного гомеостаза и лекарственное средство
RU2156621C1 (ru) * 1999-03-04 2000-09-27 Эпштейн Олег Ильич Нейротропное лекарственное средство
RU2161034C1 (ru) * 2000-08-02 2000-12-27 Новицкий Юрий Алексеевич Иммунокорригирующее протеоселеновое средство и способ иммунокоррекции

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PODKOLZIN A.A. ET AL.: "Factory maloi intensivnosti v bioaktivatsiy i immunokorrektsiy", PANAS-AERO, MOSKVA, 1995 *

Cited By (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9382332B2 (en) 2000-06-20 2016-07-05 Oleg Iliich Epshtein Method of treating a pathological syndrome and a pharmaceutical agent
US9303090B2 (en) 2000-06-20 2016-04-05 Oleg Iliich Epshtein Method of treating a pathological syndrome and a pharmaceutical agent
US8871203B2 (en) 2000-06-20 2014-10-28 Oleg I. Epshtein Method of treating a pathological syndrome and a pharmaceutical agent
US9228024B2 (en) 2000-06-20 2016-01-05 Oleg Iliich Epshtein Method of treating hypertension disorder and a pharmaceutical agent
US9200081B2 (en) 2000-06-20 2015-12-01 Oleg Iliich Epshtein Method for administering homeopathically potentiated antibodies against mediator of inflammation
US8894995B2 (en) 2000-06-20 2014-11-25 Oleg Iliich Epshtein Method of treating a disorder or condition of viral etiology
US8535664B2 (en) 2000-06-20 2013-09-17 Oleg I. Epshtein Method of treating a pathological syndrome and a pharmaceutical agent
US7700096B2 (en) 2002-08-02 2010-04-20 Oleg Iliich Epshtein Medicinal agent for treating erectile dysfunction
US8066992B2 (en) 2002-08-02 2011-11-29 Oleg Iliich Epshtein Medicament and a method of treating a pathological syndrome
US8815245B2 (en) 2002-08-02 2014-08-26 Oleg I. Epshtein Method of treating viral diseases
US8637030B2 (en) 2010-07-15 2014-01-28 Oleg I. Epshtein Combination pharmaceutical composition and methods of treating functional diseases or conditions of gastrointestinal tract
CN103282384A (zh) * 2010-07-15 2013-09-04 奥列格·伊里奇·爱泼斯坦 复合药物组合物以及对泌尿生殖系统障碍进行治疗的方法
GB2497453A (en) * 2010-08-06 2013-06-12 Oleg Lliich Epshtein Pharmaceutical composition and methods of treating and preventing the diseases caused by HIV or associated with HIV
WO2012017327A3 (fr) * 2010-08-06 2012-04-12 Oleg Iliich Epshtein Composition pharmaceutique et méthodes de traitement et de prévention des maladies provoquées par le vih ou associées au vih
EP2601967A4 (fr) * 2010-08-06 2014-05-07 Oleg Iliich Epshtein Médicament destiné à la prévention et au traitement des maladies provoquées par le vih ou associées au vih, y compris du sida
EP2601967A1 (fr) * 2010-08-06 2013-06-12 Oleg Iliich Epshtein Médicament destiné à la prévention et au traitement des maladies provoquées par le vih ou associées au vih, y compris du sida
WO2012017323A3 (fr) * 2010-08-06 2012-04-12 Oleg Iliich Epshtein Composition pharmaceutique et méthodes de traitement et de prévention des maladies provoquées par le vih ou associées au vih
ES2429422R1 (es) * 2010-08-06 2014-11-12 Oleg Iliich Epshtein Composición farmacéutica y su uso para preparar un medicamento destinado al tratamiento y la prevención de enfermedades causadas por el VIH
CN103154030A (zh) * 2010-08-06 2013-06-12 奥列格·伊里奇·爱泼斯坦 复合药物组合物以及对传染性疾病进行治疗和预防的方法
ES2510940R1 (es) * 2010-08-06 2015-03-27 Oleg Iliich Epshtein Composición farmacéutica combinada y su uso para preparar un medicamento destinado al tratamiento y prevención de las enfermedades infecciosas
ES2524385R1 (es) * 2010-08-06 2015-05-27 Oleg Iliich Epshtein Composición farmacéutica y su uso para preparar un medicamento destinado al tratamiento y la prevención de enfermedades causadas por el VIH
GB2496356A (en) * 2010-08-06 2013-05-08 Oleg Lliich Epshtein Pharmaceutical composition and method of inhibiting of production or amplifying elimination of P24 protein
WO2012017322A3 (fr) * 2010-08-06 2012-04-19 Oleg Iliich Epshtein Composition pharmaceutique et procédé d'inhibition de la production ou d'amplification de l'élimination de la protéine p24
GB2503066A (en) * 2010-08-06 2013-12-18 Oleg Lliich Epshtein Combination pharmaceutical composition and methods of treating and preventing the infectious diseases
WO2012017328A3 (fr) * 2010-08-06 2012-04-05 Oleg Iliich Epshtein Composition pharmaceutique à combinaison et méthodes de traitement et de prévention des maladies infectieuses
AU2011286486B2 (en) * 2010-08-06 2017-02-02 Oleg Iliich Epshtein Drug and method for the prophylaxis of HIV infection and for the prophylaxis and treatment of diseases caused by or associated with HIV, including aids
AU2011287292B2 (en) * 2010-08-06 2017-02-02 Oleg Iliich Epshtein Combination pharmaceutical composition and methods of treating and preventing the infectious diseases
GB2497453B (en) * 2010-08-06 2017-07-12 Oleg Iliich Epshtein Pharmaceutical composition and methods of treating and preventing the diseases caused by HIV or associated with HIV
GB2503066B (en) * 2010-08-06 2017-09-06 Oleg Iliich Epshtein Combination pharmaceutical composition and methods of treating and preventing the infectious diseases
GB2548034A (en) * 2010-08-06 2017-09-06 Iliich Epshtein Oleg Combination pharmaceutical composition and methods of treating and preventing the infectious diseases
GB2548034B (en) * 2010-08-06 2018-05-23 Iliich Epshtein Oleg Combination pharmaceutical composition and methods of treating and preventing the infectious diseases
EA029791B1 (ru) * 2010-08-06 2018-05-31 Олег Ильич ЭПШТЕЙН Фармацевтическая композиция и способ ингибирования продукции или усиления элиминации белка p24 вич
EA030513B1 (ru) * 2010-08-06 2018-08-31 Олег Ильич ЭПШТЕЙН Комбинированная фармацевтическая композиция и способ лечения и профилактики инфекционных заболеваний
EA032021B1 (ru) * 2010-08-06 2019-03-29 Олег Ильич ЭПШТЕЙН Фармацевтическая композиция и способ лечения и профилактики заболеваний, вызванных и/или ассоциированных с вич

Also Published As

Publication number Publication date
RU2001134982A (ru) 2004-02-20
AU2002313946A1 (en) 2003-07-15

Similar Documents

Publication Publication Date Title
WO2005000350A1 (fr) Medicament et methode de traitement d'un syndrome pathologique
AU2011287292B2 (en) Combination pharmaceutical composition and methods of treating and preventing the infectious diseases
RU2217152C2 (ru) Колостринин и его применение
WO2003055519A1 (fr) Agent pharmaceutique et methode de traitement de maladies s'accompagnant de troubles du tonus vasculaire
WO2004012764A1 (fr) Medicament et procede de traitement des maladies de la prostate
AU2006277295A1 (en) Glypican-3 (GPC3)-derived tumor rejection antigenic peptides useful for HLA-A2-positive patients and pharmaceutical comprising the same
RU2187334C2 (ru) Способ коррекции нарушенного иммунного гомеостаза и лекарственное средство
CN110201157A (zh) 皮肤病学病状的治疗
RU2156621C1 (ru) Нейротропное лекарственное средство
WO2004012767A1 (fr) Preparation medicinale et procede de traitement de dyserections
WO2004012766A1 (fr) Procede de correction de reactions immunitaires pathologiques et preparation medicinale
WO2003055518A1 (fr) Procede de traitement d'etats immuno-pathologiques et medicament correspondant
US3928580A (en) Injectable glycoproteins containing terminal {37 C{38 {0 ends of human immunoglobulins
JPH09502706A (ja) 胆汁由来免疫調節組成物
MXPA04007311A (es) Tratamiento de ms con suero de cabra.
Altinoz et al. Rabies virus vaccine as an immune adjuvant against cancers and glioblastoma: new studies may resurrect a neglected potential
AU2003202093A1 (en) Treatment of MS with goat serum
US9249188B2 (en) Mammalian colostrum derived nanopeptides for broadspectrum viral and recurrent infections with a method of isolation thereof
WO2003077946A1 (fr) Agent pharmaceutique et methode de traitement d'un syndrome pathologique associe a hemodyscrasia
US20210252137A1 (en) Aluminum based adjuvants for tolerogenic vaccination
RU2385164C1 (ru) ПРИМЕНЕНИЕ Fc-ФРАГМЕНТОВ ИММУНОГЛОБУЛИНА КЛАССА G В КАЧЕСТВЕ АНТИГЕНА ДЛЯ ЛЕЧЕНИЯ РЕВМАТОИДНОГО АРТРИТА, СРЕДСТВО И СПОСОБ ЛЕЧЕНИЯ
WO2003037372A1 (fr) Procede de retablissement de processus physiologiques perturbes et medicament
WO2004012765A1 (fr) Preparation medicinale et procede de traitement d'un syndrome pathologique determine par une perturbation de l'hematopoiese
RU2500427C2 (ru) Лекарственное средство для лечения функциональных нарушений желудочно-кишечного тракта и способ лечения функциональных нарушений желудочно-кишечного тракта
WO2003055517A1 (fr) Procede de correction de la reponse immunitaire et medicament

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP